Revenue growth reached 87.2% in 2026Q1, though structural profitability remains elusive as evidenced by a net loss of $32.3M and an operating margin of -2.7%.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Sales/Revenue | 40.71M | 35.26M | 22.47M | 22.39M | 16.39M | 13.68M | 4.95M | 21.3M | 18.91M | 6.37M | 332K | 38K | 0 | 17K |
| Revenue Growth % | 71.91% | 56.89% | 0.37% | 36.62% | 19.85% | 176.32% | -76.77% | 12.63% | 196.77% | 1819.58% | 773.68% | - | -100% | - |
| Cost of Goods Sold | 19.51M | 19.49M | 21.94M | 19.3M | 13.66M | 14.49M | 22.32M | 40.75M | 27.06M | 9.76M | 660K | 0 | 0 | 5K |
| COGS % of Revenue | - | 55.29% | 97.63% | 86.19% | 83.37% | 105.93% | 450.9% | 191.3% | 143.07% | 153.11% | 198.8% | - | - | 29.41% |
| Gross Profit | 21.2M | 15.76M | 533K | 3.09M | 2.73M | -811K | -17.37M | -19.45M | -8.15M | -3.38M | -328K | -80K | 0 | 12K |
| Gross Margin % | 52.07% | 44.71% | 2.37% | 13.81% | 16.63% | -5.93% | -350.9% | -91.3% | -43.07% | -53.11% | -98.8% | -210.53% | - | 70.59% |
| Gross Profit Growth % | - | 2857.41% | -82.76% | 13.39% | 436.13% | 95.33% | 10.71% | -138.74% | -140.65% | -932.01% | -310% | - | -100% | - |
| Operating Expenses | 107.89M | 84.1M | 75.38M | 78.69M | 71.35M | 56.37M | 61.76M | 111.21M | 79.43M | 52.93M | 42.1M | 28.85M | 18.7M | 18.8M |
| OpEx % of Revenue | - | 238.53% | 335.42% | 351.47% | 435.37% | 412.22% | 1248.01% | 522.11% | 419.99% | 830.5% | 12682.23% | 75921.05% | - | 110594.12% |
| Selling, General & Admin | 74.99M | 52.51M | 34.23M | 29.94M | 31.63M | 29.15M | 41.35M | 72.78M | 47.57M | 22.19M | 15.76M | 10.6M | 5.82M | 5.01M |
| SG&A % of Revenue | - | 148.93% | 152.33% | 133.73% | 193.02% | 213.19% | 835.54% | 341.69% | 251.51% | 348.23% | 4746.39% | 27892.11% | - | 29470.59% |
| Research & Development | 32.9M | 31.59M | 41.14M | 48.75M | 39.72M | 27.22M | 20.41M | 38.43M | 31.86M | 30.73M | 26.35M | 18.25M | 12.88M | 13.79M |
| R&D % of Revenue | - | 89.6% | 183.09% | 217.74% | 242.35% | 199.03% | 412.47% | 180.41% | 168.47% | 482.27% | 7935.84% | 48028.95% | - | 81123.53% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -321K | 176K | 25K | 0 | 0 | 0 |
| Operating Income | -86.69M | -68.34M | -74.84M | -75.6M | -68.63M | -57.18M | -79.13M | -130.66M | -87.58M | -56.31M | -42.43M | -28.81M | -18.7M | -18.79M |
| Operating Margin % | -212.95% | -193.83% | -333.05% | -337.66% | -418.74% | -418.15% | -1598.91% | -613.41% | -463.06% | -883.62% | -12781.02% | -75821.05% | - | -110523.53% |
| Operating Income Growth % | - | 8.69% | 1.01% | -10.17% | -20.02% | 27.74% | 39.44% | -49.2% | -55.52% | -32.71% | -47.28% | -54.06% | 0.46% | - |
| EBITDA | -85.02M | -66.83M | -73.37M | -74.33M | -67.64M | -55.94M | -77.99M | -129.66M | -87.31M | -56.09M | -42.28M | -28.69M | -18.51M | -18.57M |
| EBITDA Margin % | -208.84% | -189.54% | -326.48% | -331.96% | -412.73% | -409.09% | -1575.85% | -608.71% | -461.63% | -880.05% | -12734.34% | -75510.53% | - | -109229.41% |
| EBITDA Growth % | -24.28% | 8.92% | 1.29% | -9.88% | -20.91% | 28.27% | 39.85% | -48.51% | -55.67% | -32.66% | -47.34% | -54.99% | 0.3% | - |
| D&A (Non-Cash Add-back) | 1.67M | 1.51M | 1.48M | 1.28M | 985K | 1.24M | 1.14M | 1M | 270K | 227.27K | 155K | 118K | 189K | 220K |
| EBIT | -83.18M | -64.16M | -70.18M | -49.28M | 160.82M | -285.75M | -159M | -100.41M | -85.69M | -56M | -42.33M | -28.78M | -18.7M | -18.79M |
| Net Interest Income | -449K | -753K | -3.94M | -5.75M | -16.88M | -16.48M | -15.99M | -13.21M | -6.28M | -2.96M | -1.52M | -1.09M | 0 | 0 |
| Interest Income | 4.26M | 4.2M | 4.5M | 5.36M | 1.82M | 243K | 175K | 1.93M | 2M | 135K | 80K | 9K | 0 | 10K |
| Interest Expense | 4.71M | 4.95M | 8.44M | 11.11M | 18.7M | 16.72M | 16.17M | 15.14M | 8.28M | 3.1M | 1.6M | 1.1M | 191K | 0 |
| Other Income/Expense | -492K | -776K | -3.77M | 15.21M | 210.75M | -245.29M | -96.04M | 15.11M | -6.39M | -2.79M | -1.5M | -1.06M | -183K | 10K |
| Pretax Income | -87.19M | -69.11M | -78.62M | -60.39M | 142.12M | -302.47M | -175.17M | -115.55M | -93.97M | -59.1M | -43.93M | -29.88M | -18.89M | -18.78M |
| Pretax Margin % | -214.16% | -196.03% | -349.84% | -269.73% | 867.16% | -2211.88% | -3539.46% | -542.46% | -496.86% | -927.37% | -13231.93% | -78623.68% | - | -110464.71% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 183K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.97% | 0% |
| Net Income | -87.19M | -69.11M | -78.62M | -60.39M | 142.12M | -302.47M | -175.17M | -115.55M | -93.97M | -59.1M | -43.93M | -29.88M | -18.89M | -18.78M |
| Net Margin % | -214.16% | -196.03% | -349.84% | -269.73% | 867.16% | -2211.88% | -3539.46% | -542.46% | -496.86% | -927.37% | -13231.93% | -78623.68% | - | -110464.71% |
| Net Income Growth % | -17.82% | 12.09% | -30.18% | -142.49% | 146.99% | -72.68% | -51.6% | -22.96% | -59% | -34.53% | -47.04% | -58.2% | -0.56% | - |
| Net Income (Continuing) | -87.19M | -69.11M | -78.62M | -60.39M | 142.12M | -302.47M | -175.17M | -115.55M | -93.97M | -59.1M | -43.93M | -29.88M | -18.89M | -18.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.90 | -1.66 | -2.50 | -2.20 | -2.17 | -14.40 | -15.40 | -12.20 | -12.00 | -10.20 | -9.80 | -6.60 | -4.20 | -5.00 |
| EPS Growth % | 5.68% | 33.6% | -13.64% | -1.38% | 84.93% | 6.49% | -26.23% | -1.67% | -17.65% | -4.08% | -48.48% | -57.14% | 16% | - |
| EPS (Basic) | - | -1.66 | -2.50 | -2.20 | 6.07 | -14.40 | -15.40 | -12.20 | -12.00 | -10.20 | -9.80 | -6.60 | -4.20 | -5.00 |
| Diluted Shares Outstanding | 45.82M | 41.73M | 31.49M | 28.4M | 30.91M | 21.12M | 11.4M | 9.44M | 7.87M | 5.8M | 4.46M | 4.58M | 4.58M | 3.81M |
| Basic Shares Outstanding | 45.82M | 41.73M | 31.49M | 28.4M | 23.4M | 21.12M | 11.4M | 9.44M | 7.87M | 5.8M | 4.46M | 4.58M | 4.58M | 3.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
High cash burn rate
As reported in recent financial filings, SENS achieved a notable 87.2% year-over-year revenue growth in 2026Q1, suggesting that the company's transition toward a recurring revenue model for its 180-day CGM system is gaining traction despite the inherent friction of its clinical-based insertion requirement.
The acceleration in top-line growth indicates that the commercial partnership with Ascensia is successfully expanding the installed base. However, investors should monitor whether this growth is driven by sustainable end-user demand or inventory stocking, as the company remains in a critical phase of market penetration.
Based on the provided income statement data, gross margins have fluctuated significantly, reaching 59.3% in 2026Q1 from a low of -95.0% in 2024Q3, which highlights the company's ongoing struggle to achieve consistent manufacturing scale and pricing power within the competitive CGM landscape.
The extreme variance in gross margins suggests that the company's cost structure is highly sensitive to production volumes and potential supply chain inefficiencies. Until the company can stabilize these margins, it will remain difficult to determine if the current product economics can support long-term profitability.
According to the latest quarterly data, SG&A expenses surged to $30.2M in 2026Q1, significantly outpacing revenue growth and indicating that the company's commercialization strategy requires heavy investment that continues to pressure the bottom line and deplete available cash reserves.
The persistent elevation of SG&A relative to revenue suggests that the cost of acquiring and supporting new patients remains prohibitively high. This expense discipline warrants further investigation, as the current burn rate appears to be a structural impediment to achieving operational self-sufficiency.
As indicated by the reported net loss of $32.3M in 2026Q1, the company's earnings quality is currently strained by consistent operating deficits and ongoing stock-based compensation, which collectively dilute shareholder value while the firm attempts to navigate its early-stage commercialization phase.
The reliance on equity-based compensation and the lack of positive net income suggest that the company is prioritizing growth at the expense of near-term profitability. Investors should be cautious of the potential for further capital raises, which may be necessary to sustain operations given the current cash burn.
Based on the provided figures, the company's operating margin of -193.83% on a trailing basis raises significant questions regarding the long-term viability of the current business model, particularly when compared to the more established and profitable incumbents in the CGM market.
Short-sellers may focus on the disconnect between the company's clinical innovation and its inability to convert that technology into positive cash flow. The reliance on third-party distribution and the high friction of the insertion procedure may limit the company's ability to scale efficiently enough to overcome its fixed-cost base.
Quick answers to the most common questions about buying SENS stock.
For fiscal year 2025, Senseonics Holdings, Inc. (SENS) reported total revenue of $35.3M. This represents a 207294.1% increase compared to $0.0M in 2013.
Senseonics Holdings, Inc. (SENS) reported a net loss of $69.1M for the fiscal year ending 2025.
Senseonics Holdings, Inc. (SENS) reported an operating income of $-68.3M, resulting in an operating profit margin of -193.8%. This margin reflects the operational efficiency of the business before interest and taxes.
Senseonics Holdings, Inc. (SENS) generated $15.8M in gross profit for the year, representing a gross profit margin of 44.7%. This demonstrates the company's core pricing power and production efficiency.